Bi Eligard CP 1 Month TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: bicalutamide, inert substance, leuprorelin
Brand name
(ARTG)
: BI ELIGARD CP (Eligard 1 month 7.5mg and MPL-Bicalutamide 50mg, 28 pack)Download the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Bicalutamide,Treatment of advanced prostate cancer in combination with LHRH agonist therapy.,Leuprorelin,Eligard® is indicated for the palliative treatment of advanced prostate cancer.
How to use this medicine
(ARTG)
This medicine is a pack that contains more than one component.
Component :
- Tablet, film coated
- Oral
- a white to off-white, round, film-coated, biconvex tablet, engraved with 'BC 50' on one face and plain on the other
Component :
- Injection, modified release
- Subcutaneous
- Two-syringe system sterile 20-gauge 5/8-inch needle and silica gel desiccant.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- Single eligard injection with bicalutamide 50 mg (28 tablets) pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient bicalutamide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For the active ingredient leuprorelin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
